

## François E. Paris, Ph.D.

INSERM UMR 1232, CRCINA  
 Head of the Laboratory of "Plasticity of Tumor Ecosystem after  
 Radiotherapy"  
 8 quai Moncousu, 44047 Nantes  
 ☎: +33 (0)2.28.08.03.02; 📠: +33 (0)2.28.08.02.04  
 ✉: francois.paris@inserm.fr  
<http://www.crcina.org/recherche/departement-2-onco/equipe-14-endothelium-radiobiology-and-targeting/>

### Education and Titles

2011	INSERM Director of Research
2009	Habilitation à Diriger les Recherches, Nantes University
2002	INSERM Researcher tenure
1998	Ph.D. of Biology, Nantes University
1993	2 <sup>nd</sup> year of M.Sc, topic Radiobiology, Paris V University.
1992	1 <sup>st</sup> year of M.Sc., topic Biophysic and Cellular Biology, Paris VI University
1991	B.Sc., Topic Molecular and Cellular Biology, Nantes University

### Professional Experiences

2017	Head of Oncology Department, CRCINA, Inserm UMR1232
2013-19	Scientific adversary board of exogenbio ( <a href="http://www.exogenbio.com">http://www.exogenbio.com</a> )
2007-	Head of Endothelium Radiobiology and Targeting Lab., CRCNA UMR Inserm 892 CNRS 6299, Nantes
2004-	Project Manager in Translational Research Radiotherapy, Integrated Center of Oncology, Nantes
1998-01	Postdoctoral fellow, Signal Transduction Laboratory and Radiation Oncology Dept, MSKCC, New York, USA
1996	Trainee, Molecular Endocrinology Lab., Laval Univ., Québec, Canada
1995-98	Ph.D. Student, Molecular Radiobiology Laboratory, CEA-CNRS, Fontenay aux Roses
1994	Trainee, DNA Repair and Mutagenesis Lab., MRC Radiobiology, Didcot, UK
1993	Master II, Toxicology Lab., CNRS-Curie Institute, Paris
1992	Trainee, Biochemistry Dept, UCB Pharma, Braine L'alleud, Belgium

### Scientific Networks, Societies and Awards

2020	Scientific committee Training in basic & translational cancer res., FRFT, ITMO Cancer
2019-	Scientific evaluating committees for HCERES
2019-	Scientific evaluating committee Radiobiology call CEA-IRSN
2019-24	Scientific committee of the Radiobiology Program at ESTRO
2019-23	Genetic commission at the ARC
2018-	Evaluating committee HCERES
2017-	Scientific reviewing for Dutch Cancer Society
2016	Scientific reviewing for Cancer Research UK
2015-	Scientific committee Radiobiology at UNICANCER
2015-	Scientific reviewing for Fondation contre le Cancer (Belgique)
2014-	Inserm representative on the national committee of EURATOM
2013-17	Scientific Council of the Faculty of Medicine of Nantes
2012-17	Member of the CSS Inserm evaluation "Technology for health"
2009-12	Commission "Technology and New Therapies" at the National League Against Cancer
2008-	European network MELODI in Radiation Protection
2008-	Mélusyn network of the Synchrotron Soleil
2007-10	Member of regional project « Cimath »
2006	Award INSERM to help the transfert of the basic studies to clinic
2005-	Member of the task « Vectorisation & Radiotherapy » of the Cancéropole Grand Ouest
2005	Award Olga Sain from Ligue contre le Cancer - Comité de Paris
2000-	Member of the Radiation Research Society
1999-05	Member of American Association of Cancer Research

## Teaching

Over 20 h every year

- 2015- M.Sc. Radiation therapy. Poznan Univ, Poland. (4h, topic Radiobiology)
- 2014- M.Sc Matter Radiation Interaction. Nantes Univ. (12h, topic Radiobiology)
- 2011- M. Sc. Cancerology, Paris XI Univ. (3h, topic Radiobiology-Radiotherapy)
- 2009- M. Sc. Biology. Nantes Univ. (3h, topic Angiogenesis)

## Students

Ph.D.: Stéphanie Bonnaud (2003-7), Colin Niaudet (2005-9), Ariane Desselle (2008-11), Audrey Lafargue (2010-14), Caroline Noblet (2011-14), Mickael Terme (2011-14), Maeva Guilloneau (2012-15), Julien Fleurence (2014-17), Charlotte Degorre (2014-18), Karen Colmou (2016-19), Hala Estephan (2016-19), Theo Desigaux (2020-22), Inès El Rifai (2021-23), Hala Awada (2021-23)

Master II: Colin Niaudet (2004), Franck Drouet (2010), Lydie Allard (2011), Maria Janeh (2013), Samar Krihli (2014), Hala Estephan (2015), Charbel Touma (2018), Rima Salma (2019) ; Constance Lesage (2019) ; Guillaume Campard (2020); Julie Vignau (2020), Lea Renaud (2021), Elouan Roumeas-Noel (2021), Mehdi Kheroufi (2021)

## Peer reviewing

Editor at Cancers & Frontiers Press for Pharmacology of Anti-Cancer Drugs  
 Manuscript review for Cancer Res, PlosOne, Radiotherapy & Oncology, Exp. Cell Res, Oncogene, Radiation Res, FASEB, BBA, Cell Death & Disease, Int. J. Radioth. Phys., Biol., Cancers,  
 Grant review for INCA, ANR, Ligue regional contre le Cancer, IDEX Sorbonne, FLNQ (CA), Lung foundation (UK), Fondation Contre le Cancer (B), Dutch Cancer foundation (NL), Cancer UK

## Patents & Software

- 2015 Software Radiotherapy modelisation
- 2014 WO/2014/14305764-12/2014 "Methods for determining whether a patient will achieve a response after radiation therapy". Applicant: Inserm/ICO
- 2011 WO/2012/107424-2/2011 "Anti-Gb3 antibodies useful in treating disorders associated with angiogenesis". Applicant: IRSN & Nantes Univ.
- 2004 WO2005014643-10/2003 "New Il-11 muteins". Applicant : Inserm

## Publications & Bibliometric

ORCID ID: <https://orcid.org/0000-0002-0176-7348>

Publications: 73 (2 Sciences, 3 Nature Med., 4 Cancer Res., 4 JBC, 2 FASEB, 2 Radiot Onc,...)

[https://www.researchgate.net/profile/Francois\\_Paris/](https://www.researchgate.net/profile/Francois_Paris/)

### Web of Science

h factor: 30  
 Total citations >5600

### Google Scholar

h factor: 33  
 Total citations > 7100  
 Indice i10: 51

## Publications

### Peer-review articles

1. Le Rhun Y, Duthu A, **Paris F**, Martin M, May E. A rat organotypic model for identifying and characterizing p53 mutations induced by benzo(a)pyrene treatment. *Radioprotection*, 1996; 32 (C1): 169-170.
2. **Paris F**, Le Rhun Y, May E, Shah G, Martin M. Responses of BP cell lines after gamma irradiation: Role of the DNA repair and apoptosis mechanisms in the radiosensitivity. *Radioprotection*, 1996; 32 (C1): 195-196.
3. Biard D, Santiny Y, Maratrat M, **Paris F**, Martin M, Angulo J. Enhanced Expression of the Kin17 protein immediately after Low Doses of Ionizing. *Radiation Res.* 1997; 147(4): 442-50.

4. **Paris F**, Grassme H, Cremesti A, Zagger J, Fong Y, Haimovitz-Friedman A, Fuks Z, Gulbins E, Kolesnick R. Natural ceramide reverses Fas resistance of acid sphingomyelinase<sup>-/-</sup> hepatocytes. *JBC*. 2000; 276 (11): 8297-305
5. Cremesti A, **Paris F**, Grassme H, Holler N, Tschopp J, Fuks Z, Gulbins E, Kolesnick R. Natural ceramide confers apoptosis onto soluble Fas ligand. *JBC*. 2000; 276 (26): 23954-61
6. Kirschnek S, **Paris F**, Weller M, Grassme H, Ferlinz K, Riehle A, Fuks Z, Kolesnick R, Gulbins E. CD95-mediated apoptosis *in vivo* involves acid sphingomyelinase. *JBC*. 2000; 275 (35): 27316-23
7. Morita Y, Perez GI, **Paris F**, Miranda SR, Ehleiter D, Haimovitz-Friedman A, Fuks Z, Xie Z, Reed JC, Schuchman EH, Kolesnick RN, Tilly JL. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. *Nature Med*. 2000; 6 (10):1109-14
8. Lin T, Genestier L, Pinkoski MJ, Castro A, Nicholas S, Mogil R, **Paris F**, Fuks Z, Schuchman E, Kolesnick R, Green D Role of Acidic Sphingomyelinase in Fas/CD95-mediated Cell Death. *JBC*. 2000; 275 (12): 8657-63
9. **Paris F**, Fuks Z, Kang A, Capodiec P, Juan G, Ehleiter D, Haimovitz-Friedman A, Cordon-Cardo C, Kolesnick R. Endothelial apoptosis is the primary lesion initiating radiation damages to the intestines. *Science*. 2001; 293 (5528): 293-97
10. Bravard A, Ageron-Blanc A, Alvarez S, Drane P, Le Rhun Y, **Paris F**, Luccioni C, May E. Correlation between antioxidant status, tumorigenicity and radiosensitivity in sister rat cell lines. *Carcinogenesis*. 2002; 23(5):705-11.
11. **Paris F**, Perez GI, Haimovitz-Friedman A, Nguyen H, Fuks Z, Bose M, Iligan A, Hunt P, Morgan WF, Tilly JL, Kolesnick R. Sphingosine 1-phosphate preserves fertility in irradiated female without propagating genomic damage in offspring. *Nature Med*. 2002; 8 (9):901-902
12. Li CM, Park JH, Simonaro CM, He X, Gordon RE, Friedman AH, Ehleiter D, **Paris F**, Manova K, Hepbiloikler S, Fuks Z, Sandhoff K, Kolesnick R, Schuchman EH. Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. *Genomics*. 2002; 79(2): 218-24.
13. Maj JG, **Paris F**, Haimovitz-Friedman A, Venkatraman E, Kolesnick R, Fuks Z. Microvascular function regulates intestinal crypt response to radiation. *Cancer Res*. 2003; 63(15): 4338-41
14. Garcia-Barros M, **Paris F**, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. *Science*. 2003; 300(5622): 1155-9.
15. Ch'ang HJ, Maj JG, **Paris F**, Xing HR, Haimovitz-Friedman A, Cardon-Cardo C, Kolesnick R, Fuks Z. ATM regulates target switching to escalating doses of radiation in the Intestines. *Nature Med*. 2005; 11(5):484-90
16. Bonnaud S, Niaudet C, Pottier G, Gaugler MH, Millour J, Barbet J, Sabatier L, **Paris F**. Sphingosine-1-Phosphate protects proliferating endothelial cells from ceramide-induced apoptosis, but not from DNA damage-induced mitotic death. *Cancer Res*. 2007; 67(4):1803-11.
17. Gaugler MH, Neunlist M, Aubert P, Bonaud S, Benderitter M, **Paris F**. Intestinal epithelial cell dysfunction is mediated by an endothelial specific radiation-induced bystander effect. *Radiation Res*. 2007; 167: 185-93
18. Alvarez-Rueda N., Leprieur S., Clemenceau B., Supiot S., Sébille-Rivain V., Faivre-Chauvet A., Davodeau F., **Paris F**, Barbet J., Aubry J., Birklé S. Binding activities and antitumoral properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen. *Clin. Cancer Res*. 2007;13(18): 5613s-5620s.
19. Neunlist M, Aubert P, Bonnaud S, Lardeux B, Naveilhan P, **Paris F**, Galmiche JP. Enteric glia inhibits intestinal epithelial cell proliferation partly via a TGF- $\beta$ 1 dependent pathway. *American Journal of Physiology Gastrointestinal Liver Physiol*. 2007; 292(1):G231-41

20. Lacreusette A, Lartigue A, Nguyen JM, Barbieux I, Pandolfino MC, **Paris F**, Khammari A, Dréno B, Jacques Y, Blanchard F, Godard A. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes. *J Pathol.* 2008; 216(4):451-9.
21. Salaun PY, Bodet-Milin C, Frampas E, Oudoux A, Sai-Maurel C, Faivre-Chauvet A, Barbet J, **Paris F**, Kraeber-Bodéré F. Toxicity and efficacy of combined radioimmunotherapy and Bevacizumab (Avastin) in mouse model of medullary thyroid carcinoma. *Cancer.* 2010 116(4):1053-8.
22. Kraeber-Bodéré F, Bodet-Milin C, Niaudet C, Sai-Maurel C, Moreau A, Faivre-Chauvet A, Thomare P, Deleris G, Estieu-Gionnet K, Bikfalvi A, Barbet J, **Paris F**. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in CEA-expressing medullary thyroid cancer xenograft. *J Nucl. Med.* 2010;51(4):624-31.
23. Clere N., Corre I., Faure S, Guihot AL., Vessières E., Chalopin M., Morel A., Coqueret O., Hein L., Delneste Y., **Paris F**, Henrion D.. Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. *Int. J. Cancer.* 127(10):2279-91
24. Bonnaud S, Niaudet C, Legoux F, Corre I, Delpon G, Saulquin X, Fuks Z, Gaugler MH, Kolesnick R, **Paris F**. Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis. *Cancer Res.* 2010;70(23):9905-15
25. Kumar A, Oskouian B, Fyrst H, Zhang M, **Paris F** and Saba JD. S1P lyase regulates DNA damage responses through a novel sphingolipid feedback mechanism. *Cell Death and Disease.* 2011; 2, e119
26. Alvarez-Rueda N, Desselle A, Cochonnu D, Chaumette T, Clemenceau B, Leprieur S, Bougras G, Supiot S, Mussini JM, Barbet J, Saba J, **Paris F**, Aubry J, Birkle S. A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity. *Plos One.* 2010 6(9):e25220.
27. Rousseau M, Gaugler MH, Rodallec A, Bonnaud S, **Paris F**, Corre I. RhoA GTPase regulates radiation-induced alterations in endothelial cell adhesion and migration. *Biochem Biophys Res Commun.* 2011; 4;414(4):750-5.
28. Desselle A, Chaumette T, Marie-Hélène Gaugler MH, Cochonneau D, Fleurence J, Dubois N, Hulin P, Aubry J, Birklé S, **Paris F**. Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor development. *Plos One.* 2012;7(11):e45423
29. Potiron V, Abderrahmani R, Giang E, Chiavassa S, Di Tomaso E, Maira S-M, **Paris F**, Supiot S. Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions. *Radiother Oncol.* 2013;106(1):138-46
30. Oliver L, Hue E, Séry Q, Lafargue A, Pecqueur C, **Paris F**, Vallette FM. Differentiation Related Response to DNA Breaks in Human Mesenchymal Stem Cells. *Stem Cells.* 2013, 31(4):800-7
31. Cochonneau D, Terme M, Michaud A, Dorvillius M, Gautier N, Frickeche J, Alvarez-Rueda N, Bougras G, Aubry J, **Paris F**, Birklé S. Cell cycle arrest and apoptosis induced by O-Acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo. *Cancer Letters.* 2013 ; 333(2):194-204
32. Birklé S, Desselle A, Chaumette T, Gaugler M.H, Cochonneau D, Fleurence J, Dubois N, Hulin P, Aubry J, and **Paris F**. Inhibition of tumor angiogenesis by globotriaosyl ceramide Gb3 immunotargeting. *Oncoimmunology.* 2013 ; 2(4):e23700.
33. Noblet C, Chiavassa S, **Paris F**, Supiot S, Lisbona A, Delpon G. Underestimation of dose delivery in preclinical irradiation due to scattering conditions. *Phys Med.* 2014 :63-8.
34. Potiron VA, Abderrahmani R, Clément-Colmou K, Marionneau-Lambot S, Oullier T, **Paris F**, Supiot S. Improved functionality of the vasculature during conventionally fractionated radiation therapy of prostate cancer. *PLoS One.* 2013. 8(12):e84076.
35. Terme M, Dorvillius M, Cochonneau D, Chaumette T, Xiao W, Diccianni MB, Barbet J, Yu AL, **Paris F**, Sorkin LS, Birklé S. Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same

- Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia. *PLoS One*. 2014. 10;9(2):e87210.
36. Brocard E, Oizel K, Laliér L, Pecqueur C, **Paris F**, Vallette FM, Oliver L. Radiation-induced PGE2 sustains human glioma cells growth and survival through EGF signaling. *Oncotarget*. 2015;6(9):6840-9. doi: 10.18632/oncotarget.3160.
  37. Noblet C, Chiavassa S, Smekens F, Sarrut D, Passal V, Suhard J, Lisbona A, **Paris F**, Delpon G. Validation of fast Monte Carlo dose calculation in small animal radiotherapy with EBT3 radiochromic films. *Phys Med Biol*. 2016. 7;61(9):3521-35. doi: 10.1088/0031-9155/61/9/3521.
  38. Dubois N, Rio E, Ripoche E, Ferchaud-Rouche V, Gaugler MH, Campion L, Krempf M, Carrie C, Mahé M, Mirabel X, **Paris F**. Plasma ceramide, a real-time predictive marker of pulmonary and hepatic metastases response to stereotactic body radiation therapy combined with irinotecan. *Radiother Oncol*. 2016. 119(2):229-35. doi: 10.1016/j.radonc.2016.03.014.
  39. Silva V, Lafont F, Benhelli-Mokrani H, LeBreton M, Hulin P, Chabot T, **Paris F**, Sakanyan V, Fleury F. Rapid diminution in the level and activity of DNA-dependent protein kinase in cancer cells by a reactive nitro-benzoxadiazole compound. *Int. J. Mol Sciences*. 2016. 17(5):703. doi: 10.3390/ijms17050703.
  40. Guillonneau M, **Paris F**, Dutoit S, Estéphan H, Bénéteau E, Huot J, Corre I. Oxidative stress disassembles the p38 /NPM/PP2a complex leading to the modulation of NPM-mediated signaling to DNA damage response. *FASEB J*. 2016. 30(8):2899-914. doi: 10.1096/fj.201500194R.
  41. Fleurence, J, Cochonneau D, Fougeray S, Oliver L, Geraldo F, Dorvillius M, Loussouarn D, Vallette F, **Paris F**, Birkle S. Targeting and killing glioblastoma with monoclonal antibody to O-acetyl-GD2 ganglioside. *Oncotarget*. 2016. 5;7(27):41172-85. doi: 10.18632/oncotarget.9226.
  42. Fadous-Khalifé MC, Aloulou N, Jalbout M, Hadchity J, Aftimos G, **Paris F**, Hadchity E. Krüppel-like factor 4: A new potential biomarker of lung cancer. *Mol Clin Oncol*. 2016. 5(1):35-40. doi: 10.3892/mco.2016.883.
  43. Niaudet C, Bonnaud S, Guillonneau M, Gouard S, Gaugler MH, Dutoit S, Ripoche N, Dubois N, Trichet V, Corre I, **Paris F**. Plasma membrane reorganization links acid sphingomyelinase /ceramide to p38 MAPK pathways in endothelial cells apoptosis. *Cell. Signal*. 2017. ;33:10-21. PMID: 28179144. doi: 10.1016/j.cellsig.2017.02.001.
  44. Lafargue A, Degorre C, Corre I, Alves-Guerra MC, Gaugler MH, Vallette F, Pecqueur C, **Paris F**. Ionizing radiation induces long-term senescence in endothelial cells through mitochondrial respiratory complex II dysfunction and superoxide generation. *Free Radic Biol Med*. 2017. 108:750-59. doi: 10.1016/j.freeradbiomed.2017.04.019.
  45. Paul-Gilloteaux P, Potiron V, Delpon G, Supiot S, Chiavassa S, **Paris F**, Costes SV. Optimizing radiotherapy protocols using computer automata to model tumor cell death in function of oxygen diffusion processes. *Sci Rep*. 2017. 23;7(1):2280. doi: 10.1038/s41598-017-01757-6.
  46. Noblet C, Delpon G, Supiot S, Potiron V, **Paris F**, Chiavassa S. A new tissue segmentation method to calculate 3D dose in small animal radiation therapy. *Radiat Oncol*. 2018. 13(1):32. doi: 10.1186/s13014-018-0971-8.
  47. Supiot S, Rousseau C, Dore M, Cheze-Le-Rest C, Kandel-Aznar C, Potiron V, Guerif S, **Paris F**, Ferrer L, Campion L, Meingan P, Delpon G, Hatt M, Visvikis D. Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using <sup>18</sup>F-fluoromisonidazole PET/CT: a pilot study. *Oncotarget*. 2018. 13;9(11):10005-15. doi: 10.18632/oncotarget.24234.
  48. Supiot S, Rousseau C, Dore M, Chèze-Le-Rest C, Kandel-Aznar C, Potiron V, Guerif S, **Paris F**, Ferrer L, Campion L, Meingan P, Delpon G, Hatt M, Visvikis D. Reoxygenation during radiotherapy in intermediate-risk prostate cancer. *Radiother Oncol*. 2019.133:16-19. doi: 10.1016/j.radonc.2018.12.022.
  49. Sosa Marrero C, Acosta O, Castro M, Hernandez, Rioux-Leclercq N, Paris F, de Crevoisier R. Sensitivity analysis of an *in-silico* model of tumor growth and radiation response. IEEE. 2019. Processing article. ISBI. doi: 10.1109/ISBI.2019.8759449

50. Potiron V, Clément-Colmou K, Jouglar E, Pietri M, Chiavassa S, Delpon G, **Paris F**, Supiot S. Tumor Vasculature Remodeling by Radiation Therapy Increases Doxorubicin Distribution and Efficacy. *Cancer Lett.* 2020. 457: 1-9. doi: 10.1016/j.canlet.2019.05.005.
51. Fleurence J, Bahri M, Fougeray S, Faraj S, Vermeulen S, Pinault E, Geraldo F, Oliver O, Vézières J, Marquet P, Rabé M, Gratas C, Vallette F, Pecqueur C, **Paris F**, Birklé S. Impairing Temozolomide Resistance Driven by Glioma Stem-Like Cells With Adjuvant Immunotherapy Targeting O-acetyl GD2 Ganglioside. *Int. J. Cancer.* 2020. 146 (2): 424-38. doi: 10.1002/ijc.32533
52. Clément-Colmou K, Potiron V, Pietri M, Guillonnet M, Jouglar E, Chiavassa S, Delpon G, **Paris F**, Stéphane Supiot. Influence of Radiotherapy Fractionation Schedule on the Tumor Vascular Microenvironment in Prostate and Lung Cancer Models. *Cancers.* 2020.12(1):121. doi: 10.3390/cancers12010121.
53. Dufresne S, Guéritat J, Chiavassa S, Noblet C, Assi M, Rioux-Leclercq N, Rannou-Bekono F, Lefeuvre-Orfila L, **Paris F**, Rébillard A. Exercise training improves radiotherapy efficiency in a murine model of prostate cancer. *FASEB J* 2020. 34(4):4984-96. doi: 10.1096/fj.201901728R.
54. Oizel K, Yang C, Renoult O, Gautier F, Do QN, Joalland N, Gao X, Ko B, Vallette F, Ge WP, **Paris F**, DeBerardinis RJ, Pecqueur C. Glutamine uptake and utilization of human mesenchymal Glioblastoma in orthotopic mouse model. *Cancer & Metabolism* 2020. 8:9. doi: 10.1186/s40170-020-00215-8.
55. Ketteler J, Leonetti D, Veas Roy V, Estéphan H, Wittka A, Maier P, Reis H, Herskind C, Jendrossek V, **Paris F**, Klein D. Caveolin 1 regulates the ASMase/ ceramide-mediated radiation-response of endothelial cells in the context of tumor-stroma-interactions. *Cell Death Dis.* 2020. 11(4):228. doi: 10.1038/s41419-020-2418-z.
56. Leonetti D, Estéphan H, Ripoche N, Dubois N, Aguesse A, Gouard S, Brossard L, Chiavassa S, Corre I, Pecqueur C, Neunlist M, Hadchity E, Gaugler MH, Mahé MM, **Paris F**. Secretion of acid sphingomyelinase and ceramide by endothelial cells contributes to radiation-induced intestinal toxicity. 2020. *Cancer Res.* 80(12):2651-62. doi: 10.1158/0008-5472.CAN-19-1527
57. Mignard V, Dubois D, Lanoé D, Joalland MP, Oliver L, Pecqueur C, Heymann D, **Paris F**, Vallette FM, Lalier L. Sphingolipids Distribution at Mitochondria-Associated Membranes (MAM) Upon Induction of Apoptosis. 2020. *J Lipid Res.* 2020. 61(7):1025-37. doi: 10.1194/jlr.RA120000628.
58. Pariset E, Penninckx S, Kerbaul CD, Guiet E, Macha AL, Cekanaviciute E, Snijders AM, Mao JH, **Paris F**, Costes SV. 53BP1 Repair Kinetics for Prediction of In Vivo Radiation Susceptibility in 15 Mouse Strains. *Radiat Res.* 2020. doi: 10.1667/RADE-20-00122.1. Accepted

## Reviews

1. **Paris F**, Perez G, Morita Y, Fuks Z, Tilly J, Kolesnick R. Inhibition de l'apoptose des ovocytes par invalidation du gène de la sphingomyélinase acide ou par traitement avec la sphingosine 1-phosphate. *Medecine/Sciences*, 2001. 17 (2): 230-1.
2. Bodet-Milin C., Salaun PY, Rousseau C, Davodeau F, Gaschet J, **Paris F**, Chérel M, Kraeber-Bodéré F. Targeted internal radiotherapy: Only or in association. *Medecine Nucléaire*. 2007. 31: 526-528
3. Little M. P., Tawn E. J., Tzoulaki I., Wakeford R., Hildebrandt G., **Paris F**, Tapio S. Elliott P. A Systematic Review of Epidemiological Associations between Low and Moderate Doses of Ionizing Radiation and Late Cardiovascular Effects, and Their Possible Mechanisms. *Radiation Res.* 2008. 169(1) :99-109
4. Little M. P., Tawn E. J., Tzoulaki I., Wakeford R., Hildebrandt G., **Paris F**, Tapio S. Elliott P. Review and meta-analysis of epidemiological associations between low/moderate doses of ionizing radiation and circulatory disease risks, and their mechanisms. *Radiat. Environ. Biophys.* 2010. 49(2):139-53.
5. Supiot S, Lisbona A, **Paris F**, Azria D., Fenoglio P. Dose painting : mythe ou réalité ? *Cancer Radiother.* 2010. 6-7:554-62

6. Corre I., Niaudet C., **Paris F.** Plasma membrane signaling induced by ionizing radiation. *Mutation Res.* 2010. 704(1-3):61-67
7. Mazon R, Anderson B, Supiot S, **Paris F**, Deutsch E. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. *Cancer Treat Rev.* 2011. 37(6):476-86.
8. Supiot S., **Paris F.** Radiobiologie appliquée à l'endothélium. *Cancer Radiother.* 2012. 16(1):11-5
9. Almaghrabi MY, Supiot S, **Paris F**, Mahé MA, Rio E. Stereotactic Body Radiation Therapy for Abdominal Oligometastases: A biological and clinical review. *Radiat Oncol.* 2012. 7(1):126.
10. Corre I, Guilloneau M, **Paris F.** Membrane signaling induced by high doses of ionizing radiation in the endothelial compartment. Relevance in radiation toxicity. *Int J Mol Sciences.* 2013. 14(11):22678-96
11. Mignard V, Lalier L **Paris F**, Vallette FM. Bioactive Lipids and the control of Bax/ Bak pro-apoptotic activity. *Cell Death Disease, Cell Death Dis.* 2014. 5:e126
12. Supiot S, Clément-Colmou K, **Paris F**, Corre I, Chiavassa S, Delpon G. Which rules apply to hypofractionated radiotherapy? *Cancer Radiother.* 2015. 19(6-7):421-5
13. Fleurence J, Fougeray S, Bahri M, Cochonneau D, Clémenceau B, **Paris F**, Heczey A, Birklé S. Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy. *J Immunol Res.* 2017; 2017. 5604891. doi: 10.1155/2017/5604891.
14. Corre I, **Paris F**, Houle F, Huot J. p38, a major pleiotropic pathway that transduces stress and metastatic signals in endothelial cells. *Oncotarget.* 2017. 8:55684-714. doi: 10.18632/oncotarget.18264.
15. Faraj S, Bahri M, Fougeray S, El Roz A, Fleurence J, Véziers J, Leclair MD, Thébaud E, **Paris F**, Birklé S. Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside. *Oncoimmunology.* 2017. 7(1):e1373232. doi: 10.1080/2162402X.2017.1373232.
16. Garnier D, Renoult O, Alves-Guerra MC, **Paris F**, Pecqueur C. Glioblastoma Stem-Like Cells, Metabolic Strategy to Kill a Challenging Target. *Front Oncol.* 2019. 9:118. doi: 10.3389/fonc.2019.00118.
17. Averbeck D, Candéias S, Chandna S, Foray N, Friedl AA, Haghdoost S, Jeggo PA, Lumniczky K, **Paris F**, Quintens R, Sabatier L. Establishing Mechanisms Affecting the Individual Response to Ionizing Radiation. *Int J Radiat Biol.* 2020. 96(3):297-323. doi: 10.1080/09553002.2019.1704908.